Evolent Health has appointed Archie Mayani as chief product officer. Mayani brings over 20 years of experience in healthcare technology and AI innovation from roles at GHX, Change Healthcare, UnitedHealth Group and Amazon. Most recently, Mayani served as CPO at GHX, where she developed AI-powered capabilities for healthcare supply chains. At Change Healthcare, she led clinical decision support and revenue cycle platforms, focusing on reducing administrative burden in prior authorisation. During her time at Optum and UnitedHealth Group, she scaled value-based care programmes that improved Medicare STARS performance and reduced hospital utilisation. Mayani also served as global head of product and content operations for Amazon Prime Video. She has received multiple industry honours, including the Global CPO Award in 2025 and Inspiring Leader Award in 2023.

Evolent Health faces a shifting investment narrative after analysts reset expectations, with fair value estimates dropping from $8.50 to $5.18. The revision reflects concerns about reserves, leverage and margin visibility. Despite lowered price targets, Oppenheimer, BTIG, UBS, Citi, Truist and Canaccord maintain positive ratings, citing conservative reserving and new contracts as potential margin support. Analysts view new CFO Mario Ramos as bringing increased transparency. However, KeyBanc downgraded to Sector Weight, highlighting leverage at approximately 7x and limited EBITDA recovery visibility. Multiple firms reduced 2026-2028 earnings assumptions amid medical cost pressures and ACA exchange membership concerns. Evolent recorded a $398 million goodwill impairment for Q4 2025 and issued 2026 revenue guidance of $2.4 billion to $2.6 billion.